POSTN and asthma: Besides, post-hoc analyses suggested potential benefits in subgroups, such as patients with FEV1 reversibility ≥12% and elevated biomarkers (DPP-4, periostin), showing improvements in exacerbation rates, FEV1, and asthma control.